Increased thrombin inhibition in experimental autoimmune encephalomyelitis

Area of Science:

• Neuroimmunology
• Coagulation research
• Central nervous system (CNS) inflammation

Background:

• Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), are CNS inflammatory diseases.
• Activated coagulation factors, including thrombin, are implicated in inflammation and elevated in EAE.
• Key thrombin inhibitors in plasma and brain are antithrombin III (ATIII) and protease nexin 1 (PN-1), respectively.

Purpose of the Study:

• To measure brain thrombin inhibitory capacity and CNS levels of ATIII and PN-1 during EAE.
• To investigate the role of coagulation factors in the pathogenesis of EAE and potential relevance to MS.

Main Methods:

• Induction of acute EAE in SJL/J mice.
• Measurement of exogenous thrombin inhibition using a fluorimetric assay on Days 8, 13, and 22 post-immunization.
• Assay of PN-1 and ATIII levels in brain and spinal cord via immunohistochemistry and immunoblots.

Main Results:

• Total brain thrombin inhibitory activity increased by 32% at the peak of EAE (Day 13).
• Brain ATIII levels significantly increased (2.5-fold) at the peak of EAE and correlated with clinical scores.
• PN-1 elevations were more pronounced at the preclinical stage (Day 8, 3-fold increase) than at the clinical peak.

Conclusions:

• Increased brain thrombin inhibition during EAE likely results from elevated plasma thrombin inhibitors entering the CNS.
• Early changes in PN-1 levels during EAE suggest it as a potential therapeutic target for MS.
• Coagulation system modulation may offer novel treatment strategies for MS and related CNS inflammatory conditions.